Aytu Biopharma (AYTU) EBIT (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of EBIT data on file, last reported at -$4.1 million in Q1 2026.

• On a quarterly basis, EBIT fell 267.86% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was -$15.2 million, a 512.07% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 391.95% from the prior year.
• EBIT for Q1 2026 stood at -$4.1 million, down from -$2.0 million in the prior quarter.
• Over the last five years, EBIT for AYTU reached as high as $3.1 million in Q4 2023 and fell as low as -$53.4 million in Q1 2022.
• Historically, EBIT has averaged -$6.1 million across 5 years, with a median of -$1.8 million in 2022.
• Across the five-year window, EBIT tumbled 1444.97% in 2024 and jumped 251.6% in 2025, its largest moves.
• Year by year, EBIT stood at -$6.9 million in 2022, then jumped by 145.81% to $3.1 million in 2023, then sank by 153.88% to -$1.7 million in 2024, then decreased by 16.22% to -$2.0 million in 2025, then sank by 106.29% to -$4.1 million in 2026.
• Per Business Quant data, the three most recent EBIT figures were -$4.1 million in Q1 2026, -$2.0 million in Q4 2025, and -$1.5 million in Q3 2025.